Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations / Tausch, Eugen; Ljungström, Viktor; Agathangelidis, Andreas; Zapatka, Marc; Scarfò, Lydia; Jebaraj, Billy Michael Chelliah; Yosifov, Deyan Y; Müller, Annika; Munugalavadla, Veerendra; Degenhardt, Jeremiah D; Ghia, Paolo; Rosenquist, Richard; Stilgenbauer, Stephan. - In: BLOOD. - ISSN 1528-0020. - 139:22(2022), pp. 3340-3344. [10.1182/blood.2021014550]

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations

Scarfò, Lydia;Ghia, Paolo
;
2022-01-01

2022
Cell Line, Tumor
Drug Resistance, Neoplasm
Mutation
Purines
Up-Regulation
MAP Kinase Signaling System
Quinazolinones
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/133466
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact